Logo
Logo

About Siponimod API

Product
  • Therapeutic Category中枢神经系统 (CNS)

  • API Technology

    Synthetic

  • Dose Form

    Oral Solid/Tablets

  • Dr Reddy's Development Status

    Available (Commercial)

作用机制

Siponimod is an oral, second generation sphingosine-1-phosphate receptor modulator. S1P receptor modulators can inhibit the egress and recirculation of lymphocytes from lymph nodes, a therapeutic strategy for treating certain autoimmune diseases

适应症

Secondary progressive multiple sclerosis

Dr. Reddy's的专长

Dr. Reddy's总部位于印度海得拉巴,是全球领先的活性药物成分(API)供应商之一。 Dr. Reddy's的API业务是美国、欧洲、巴西、拉丁美洲、日本、中国、韩国和新兴市场的制药公司的首选合作伙伴。

Dr. Reddy's博士的API业务在过去30多年来在开发和制造复杂API(如类固醇,多肽,复杂长链分子和高效API(HPAPI /肿瘤药物))方面所建立的深厚技术优势中茁壮成长。 我们在知识产权和法规事务方面的实力可以帮助我们始终如一地达到并超越监管标准,从而为这一专业知识提供补充。 Dr. Reddy's博士 西尼莫德 API是研发,知识产权和监管方面广泛专业知识的结果。

帮助我们的客户率先进入市场的关键组成部分是响应式供应链。 我们通过确保所有设施都高效运行并达到最新的质量,安全和生产率标准来实现这一目标。 业务和工厂之间的强大互联可以快速响应动态的市场变化,从而避免短缺并满足需求的突然激增。

RFQ Form

Phone

Related Resources

Description not provided

FAQs

What are the dosage strengths available for Siponimod API?
  • The dosage strengths available for Siponimod are 0.2 mg & 2 mg

What is Siponimod API used to treat?
  • It is a CNS drug used to treat Secondary progressive multiple sclerosis

What drug class is Siponimod API?
  • Sphingosine-1-phosphate (S1P) receptor modulator

What are offerings of Dr. Reddy's for Siponimod API?
  • Siponimod hemifumarate co-crystal (Form A)

What is the process available for ordering Siponimod API?
Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.